Task Group Charge
To decrease lung cancer deaths and increase survivorship by identifying policy pathways (Congress, federal and state agencies, state legislative, regulatory bodies, employer groups etc.) and address solutions and strategies with stakeholder groups in advocating for, improving, and ensuring access to high quality and affordable lung cancer screening and treatment including the full continuum of care; screening implementation, early detection, education, diagnosis, treatment, management, palliative and hospice care.
Leadership
Ruth C. Carlos, MD
Task Group Chair
University of Michigan
Anita McGlothlin
Task Group Vice Chair
GO2 Foundation for Lung Cancer
Task Group Members
Lori Ashby, MA
Centers for Medicare & Medicaid Services
Paul Billings
American Lung Association
Alicia Blakey, MS
American College of Radiology
Leigh Boehmer, PharmD, BCOP
Association of Community Cancer Centers
Andrea Borondy Kitts, MS, MPH
Lahey Hospital and Medical Center
Aaron Cann, MD
WellStar Health System (GA)
Mythreyi Chatfield, PhD
American College of Radiology
Ruth Carlos, MD, MS
University of Michigan
Sarah Downer, JD
The Center for Health Law and Policy Innovation of Harvard Law School
Jane Kim, MD, MPH*
Department of Veterans Affairs
Bryan Loy, MD, MBA*
Humana
Megan Marcinko, MPS
American College of Radiology
Katie McMahon, MPH
American Cancer Society Cancer Action Network
Stephen Metz
Siemens Healthineers
Bruce Pyenson, FSA, MAAA
Milliman
Lori Sakoda, PhD, MPH
Kaiser Permanente
Tina Tailor, MD
Duke University
Jan Towers, PhD, NP-C, CRNP
American Association of Nurse Practitioners
Peter Weems
National Electrical Manufacturers Association
(*) indicates Steering Committee member
Opportunities for Policy Modifications:
• Engage policy leaders to ensure the safe, responsible and equitable implementation of lung cancer screening and treatment opportunities along the treatment course and to bring proper health messages to those at risk
• Create collaborations and relationships with professional and advocacy societies and outreach to public and private payers to affect change at the policy level
• Reduce barriers to access and ensure high quality affordable preventive, screening and treatment services remain available to those at risk
• Ensure public health strategies are provided with sufficient funding to support the adoption and application of lung cancer preventive, screening and treatment services
• Build greater awareness about the importance of screening in the continuum of care among policy leaders
• Accelerate federal research and early detection funding for lung cancer prevention and control
• Promote coverage, education, and quality of delivery